Vor Bio
VOR · Nasdaq · United States
Share price · VOR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VOR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 23 Sep 2026-12.0%
Nothing announced by VOR that day or the session before.
- 2 Sep 2026+9.4%
Nothing announced by VOR that day or the session before.
- 30 Jul 2026+11.5%
Nothing announced by VOR that day or the session before.
- 21 Jul 2026+14.9%
Nothing announced by VOR that day or the session before.
- 2 Jul 2026+12.0%
Nothing announced by VOR that day or the session before.
- 29 Jun 2026+15.5%
Nothing announced by VOR that day or the session before.
- 27 May 2026+10.1%
Nothing announced by VOR that day or the session before.
- 31 Mar 2026+21.4%
Nothing announced by VOR that day or the session before.
Share of unusual movement by asset
For each asset, the share of VOR's own-move activity since 14 Oct 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Telitaciceptevents and moves
| 3 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 0% |
| Sessions with no dated event | — | 99% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | BAFF / APRILProtein / enzyme therapeutic | Rheumatoid ArthritisIgA NephropathySjögren's DiseaseMyasthenia Gravis Generalized Myasthenia Gravis |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
March 2027 (1)
What to watch
2028 (1)
December 2028 (1)
What to watch
2029 (1)
May 2029 (1)
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $35M | $79M+ $403M short-term inv. | $87M-$33M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $26M | $108M+ $358M short-term inv. | $63M-$25M operating cash flow | report ↗ |
| 2026-Q1 | — | $18M | $170M+ $322M short-term inv. | $220M-$38M operating cash flow | report ↗ |
| 2025-Q3 | — | $14M | $160M+ $10M short-term inv. | $813M-$54M operating cash flow | report ↗ |
| 2025-Q2 | — | $262M | $191M+ $10.0M short-term inv. | $1.6B-$35M operating cash flow | report ↗ |
| 2025-Q1 | — | $27M | $50M+ $10.0M short-term inv. | $32M-$31M operating cash flow | report ↗ |
| 2024-Q3 | — | $22M | $53M+ $10M short-term inv. | $28M-$23M operating cash flow | report ↗ |
| 2024-Q2 | — | $22M | $76M+ $9.9M short-term inv. | $28M-$22M operating cash flow | report ↗ |
| 2024-Q1 | — | $24M | $45M+ $63M short-term inv. | $31M-$30M operating cash flow | report ↗ |
| 2023-Q3 | — | $28M | $45M+ $115M short-term inv. | $33M-$28M operating cash flow | report ↗ |
| 2023-Q2 | — | $24M | $32M+ $155M short-term inv. | $30M-$24M operating cash flow | report ↗ |
| 2023-Q1 | — | $22M | $42M+ $168M short-term inv. | $28M-$24M operating cash flow | report ↗ |
| 2022-Q3 | — | $17M | $61M+ $75M short-term inv. | $24M-$19M operating cash flow | report ↗ |
| 2022-Q2 | — | $15M | $63M+ $88M short-term inv. | $22M-$25M operating cash flow | report ↗ |
| 2022-Q1 | — | $15M | $90M+ $92M short-term inv. | $23M-$23M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $322M | $396M+ $59M short-term inv. | $174M-$143M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $93M | $82M+ $10.0M short-term inv. | $29M-$100M operating cash flow | report ↗ |
| 2023-FY | — | $94M | $31M+ $106M short-term inv. | $29M-$100M operating cash flow | report ↗ |
| 2022-FY | — | $65M | $58M+ $173M short-term inv. | $23M-$85M operating cash flow | report ↗ |
| 2021-FY | — | $48M | $120M+ $88M short-term inv. | $17M-$69M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 16 sales ($49.4M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-02 | Sokolove Jeremy Brett · Chief Medical Officer | Tax withholding | 1,917 | $19.25 | $37K | Form 4 |
| 2026-10-02 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Option exercise | 500 | $12.80 | $6K | Form 4 |
| 2026-10-02 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Option exercise (derivative) | 500 | — | — | Form 4 |
| 2026-08-24 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Option exercise | 1,500 | $3.74 | $6K | Form 4 |
| 2026-08-24 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Option exercise (derivative) | 1,500 | — | — | Form 4 |
| 2026-07-16 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Option exercise | 2,100,000 | $0.00 | $4K | Form 4 |
| 2026-07-16 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Open-market sale | 213 | $19.75 | $4K | Form 4 |
| 2026-07-16 | RA CAPITAL MANAGEMENT, L.P.; RA Capital Healthcare Fund LP; Kolchinsky Peter; Shah Rajeev M. · 10% owner; 10% owner; 10% owner; 10% owner | Option exercise (derivative) | 2,100,000 | $5.00 | $10.5M | Form 4 |